We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
EKF Diagnostics Holdings PLC | AQSE:EKF.GB | Aquis Stock Exchange | Ordinary Share | GB0031509804 | Ordinary Shares 1p |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.348 | -1.31% | 26.152 | 24.00 | 29.00 | 26.50 | 26.152 | 26.50 | 10,000 | 14:05:24 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMEKF
RNS Number : 4268X
EKF Diagnostics Holdings PLC
25 April 2023
EKF Diagnostics Holdings plc
("EKF" or the "Company")
Total Voting Rights
EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics business, refers to its announcement dated 23 March 2023 regarding the disposal of Advanced Diagnostic Laboratory LLC ("ADL Health") (the "Disposal").
Part of the consideration for ADL Health comprised the return of 1,200,000 ordinary shares of 1p each in the capital of the Company ("Ordinary Shares") which had originally been issued as part of the payment made to the vendors of ADL Health when it was acquired by EKF in 2021. The Company now confirms that these 1,200,000 Ordinary Shares have now been received by EKF and are being held in treasury.
As a result, the Company's total issued share capital now consists of 454,930,564 Ordinary Shares with one voting right per share. The Company holds 1,200,000 Ordinary Shares in treasury. The total number of voting rights in the Company is therefore 453,730,564.
The above figure of 453,730,564 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.
EKF Diagnostics Holdings plc www.ekfdiagnostics.com Julian Baines, Executive Chair / Marc Tel: +44 (0)29 2071 0570 Davies, CFO Singer Capital Markets (Nominated Adviser & Tel: +44 (0)20 7496 3000 Broker) Aubrey Powell / George Tzimas / Oliver Platts Walbrook PR Limited Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com Paul McManus / Lianne Applegarth Mob: +44 (0)7980 541 893 / +44 (0)7584 391 303
About EKF Diagnostics Holdings plc ( www.ekfdiagnostics.com )
EKF is an AIM-listed global diagnostics business focussed on:
-- Point-of-Care analysers in the key areas of Hematology and Diabetes, as well as Central Laboratory products including clinical chemistry reagents, analysers and centrifuges
-- Life Sciences services provide specialist manufacture of enzymes and custom products for use in diagnostic food and industrial applications, as well as other higher value Contract Manufacturing services
EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
TVREASLSAEDDEFA
(END) Dow Jones Newswires
April 25, 2023 11:10 ET (15:10 GMT)
1 Year EKF Diagnostics Chart |
1 Month EKF Diagnostics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions